Study guide

8.2 Universal Immunization Programme (UIP) & Child Vaccines

Combined Medical Services Examination UPSC CMS

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Logistics & Pattern

1.1 UPSC CMS Examination Overview & Eligibility 1.2 Two-Paper Written Exam Pattern & Negative Marking 1.3 Personality Test, Service Allocation & Career Paths

2 Chapter 2: General Medicine - Cardiology & Respiratory

2.1 Coronary Artery Disease & Acute Myocardial Infarction 2.2 Heart Failure & Cardiac Arrhythmias 2.3 Community-Acquired Pneumonia & Pulmonary Tuberculosis 2.4 COPD, Bronchial Asthma & Pulmonary Embolism

3 Chapter 3: General Medicine - Gastroenterology & Hepatology

3.1 Peptic Ulcer Disease & Upper GI Bleeding 3.2 Liver Cirrhosis & Portal Hypertension 3.3 Acute & Chronic Viral Hepatitis & Pancreatitis 3.4 Inflammatory Bowel Disease & Malabsorption Syndromes

4 Chapter 4: General Medicine - Nephrology & Endocrinology

4.1 Acute Kidney Injury & Chronic Kidney Disease 4.2 Glomerulonephritis, Nephrotic Syndrome & Electrolyte Imbalances 4.3 Diabetes Mellitus: Diagnosis, Complications & Management 4.4 Thyroid Disorders & Adrenal Gland Dysfunction

5 Chapter 5: General Medicine - Neurology, Haematology & Infection

5.1 Cerebrovascular Accidents (Stroke) & Epilepsy 5.2 Approach to Anaemia: Microcytic, Megaloblastic & Haemolytic 5.3 Acute & Chronic Leukaemias and Lymphomas 5.4 Tropical & Endemic Infections: Malaria, Typhoid & Dengue

6 Chapter 6: General Medicine - Emergency Medicine & Toxicology

6.1 Acute Anaphylaxis, Sepsis & Cardiopulmonary Resuscitation 6.2 Organophosphate, Paracetamol & Snakebite Toxicology 6.3 Common Dermatological & Psychiatric Manifestations in Internal Medicine 6.4 Musculoskeletal System & Adult Rheumatology

7 Chapter 7: Paediatrics - Neonatology & Child Growth

7.1 Newborn Care, Neonatal Resuscitation & APGAR Score 7.2 Prematurity, Low Birth Weight & Neonatal Jaundice 7.3 Infant & Child Growth & Developmental Milestones

8 Chapter 8: Paediatrics - Child Health & Nutrition

8.1 Protein-Energy Malnutrition (PEM) & Micronutrient Deficiencies 8.2 Universal Immunization Programme (UIP) & Child Vaccines 8.3 Pediatric Diarrhoea, Dehydration & Respiratory Emergencies 8.4 Birth Defects, Genetic Counseling, Autism & Paediatric Accidents/Poisoning

9 Chapter 9: Surgery - General Surgery, Wounds & Shock

9.1 Wound Healing, Surgical Site Infections & Gas Gangrene 9.2 Pathophysiology of Shock & Perioperative Fluid Therapy 9.3 Acute Abdomen: Appendicitis, Peritonitis & Intestinal Obstruction 9.4 Classification, Resuscitation & Management of Thermal Burns 9.5 Medicolegal & Ethical Issues in Surgery

10 Chapter 10: Surgery - Surgical Specialties I

10.1 Inguinal, Femoral & Ventral Hernias 10.2 Benign Breast Diseases & Breast Carcinoma 10.3 Solitary Thyroid Nodule & Thyroid Carcinoma 10.4 Benign Prostatic Hyperplasia & Renal Calculi

11 Chapter 11: Surgery - ENT, Orthopaedics & Anaesthesia

11.1 Acute Otitis Media, Tonsillitis & Epistaxis 11.2 Cataract, Glaucoma & Red Eye Emergencies 11.3 Principles of Fracture Management & Common Dislocation 11.4 Principles of Local, Regional & General Anaesthesia 11.5 Neurosurgery: Raised ICP, Head Injury & CNS Lesions 11.6 Thoracic Surgery: Chest Trauma, Pleural & Lung Disease

12 Chapter 12: Obstetrics - Antenatal Care & Complications

12.1 Antenatal Care, Maternal Nutrition & Fetal Assessment 12.2 Preeclampsia, Eclampsia & Gestational Hypertension 12.3 Antepartum Haemorrhage: Placenta Previa & Abruptio Placentae 12.4 Anemia in Pregnancy & Gestational Diabetes Mellitus 12.5 Spontaneous & Recurrent Abortion: Recognition & Management

13 Chapter 13: Obstetrics & Gynaecology - Labor & PPH

13.1 Normal Labor Mechanisms & Partograph Monitoring 13.2 Malpresentations, Breech & Obstructed Labor 13.3 Postpartum Haemorrhage (PPH) Causes & Management 13.4 Puerperal Sepsis & Postnatal Maternal Care

14 Chapter 14: Gynaecology & Family Planning

14.1 Abnormal Uterine Bleeding & Uterine Fibroids 14.2 Cervical Screening (Pap Smear) & Pelvic Inflammatory Disease 14.3 Temporary & Permanent Contraceptive Methods in India 14.4 Medical Termination of Pregnancy (MTP): Law & Methods

15 Chapter 15: PSM - Epidemiology & Biostatistics

15.1 Principles of Epidemiology & Disease Transmission 15.2 Observational & Experimental Epidemiological Study Designs 15.3 Evaluation of Screening Tests: Sensitivity, Specificity & Predictive Value 15.4 Biostatistics: Sampling, Central Tendency & Significance Testing

16 Chapter 16: PSM - Disease Epidemiology & Programmes

16.1 Epidemiology & Control of TB, Malaria & Dengue 16.2 National Tuberculosis Elimination Programme & NVBDCP 16.3 Epidemiology of Hypertension, Diabetes & Cancer in India 16.4 Cold Chain Management & Vaccine Logistics in India 16.5 Genetics and Health: Inheritance, Screening & Counseling

17 Chapter 17: PSM - Health Planning & Environmental Health

17.1 Demography, Fertility Rates & Family Welfare Indicators 17.2 Safe Water Supply, Waste Disposal & Air Pollution 17.3 Occupational Health Hazards & Pneumoconioses 17.4 Health Care Delivery System, Ayushman Bharat & National Health Mission 17.5 International Health: WHO, Global Agencies & SDG 3 17.6 Medical Sociology & Health Education

8.2 Universal Immunization Programme (UIP) & Child Vaccines

Key Takeaways Explain This Topic AI

India's Universal Immunization Programme (UIP) provides free vaccination against 12 vaccine-preventable diseases, including national coverage for Diphtheria, Pertussis, Tetanus, Polio, Measles, Rubella, severe TB, Hep B, and Hib.

Birth doses comprise BCG (0.05 mL intradermal in left upper arm), bOPV (2 drops oral), and Hepatitis B birth dose (0.5 mL IM anterolateral thigh within 24 hours).

Primary infant series at 6, 10, and 14 weeks includes Pentavalent (0.5 mL IM), bOPV (2 drops oral), Rotavirus (5 drops oral), fIPV (0.1 mL ID at 6 & 14 weeks), and PCV (0.5 mL IM at 6 & 14 weeks with booster at 9 months).

Measles-Rubella (MR) vaccine is administered subcutaneously in the right upper arm at 9–12 months (MR-1) alongside Vitamin A (100,000 IU) and at 16–24 months (MR-2).

Cold chain integrity requires storing vaccines at +2°C to +8°C in Ice-Lined Refrigerators (ILRs), while OPV is kept at -20°C in Deep Freezers; Open Vial Policy applies to select liquid vaccines but strictly excludes reconstituted live vaccines (BCG, MR, JE).

Last updated: July 2026

Universal Immunization Programme (UIP) & Vaccine Guidelines

The Universal Immunization Programme (UIP) in India is one of the largest public health interventions in the world. Originally launched as the Expanded Programme on Immunization (EPI) in 1978, it was renamed UIP in 1985. UIP currently protects children against 12 Vaccine-Preventable Diseases (VPDs) :

Nationally (9 diseases) : Tuberculosis, Diphtheria, Pertussis, Tetanus, Poliomyelitis, Hepatitis B, Measles, Rubella, and Haemophilus influenzae type b (Hib) meningitis/pneumonia.

Sub-nationally / Endemic States (3 diseases) : Rotavirus diarrhea, Pneumococcal pneumonia (PCV), and Japanese Encephalitis (JE).

National Immunization Schedule (UIP India)

  • Age Target Vaccine Dose Route Anatomical Site
  • At Birth BCG 0.05 mL Intradermal (ID) Left Upper Arm (deltoid)
  • bOPV (Zero dose) 2 drops Oral Mouth
  • Hepatitis B (Birth dose) 0.5 mL Intramuscular (IM) Anterolateral thigh (left) within 24h
  • 6 Weeks Pentavalent-1 (DPT+HepB+Hib) 0.5 mL IM Anterolateral mid-thigh (left)
  • bOPV-1 2 drops Oral Mouth
  • Rotavirus-1 5 drops Oral Mouth
  • fIPV-1 (Fractional IPV) 0.1 mL Intradermal (ID) Right Upper Arm
  • PCV-1 (Pneumococcal) 0.5 mL IM Anterolateral mid-thigh (right)
  • 10 Weeks Pentavalent-2 0.5 mL IM Anterolateral mid-thigh (left)
  • bOPV-2 2 drops Oral Mouth
  • Rotavirus-2 5 drops Oral Mouth
  • 14 Weeks Pentavalent-3 0.5 mL IM Anterolateral mid-thigh (left)
  • bOPV-3 2 drops Oral Mouth
  • Rotavirus-3 5 drops Oral Mouth
  • fIPV-2 0.1 mL Intradermal (ID) Right Upper Arm
  • PCV-2 0.5 mL IM Anterolateral mid-thigh (right)
  • 9–12 Months MR 1st Dose (Measles-Rubella) 0.5 mL Subcutaneous (SC) Right Upper Arm
  • JE 1st Dose (Endemic districts) 0.5 mL Subcutaneous (SC) Left Upper Arm
  • PCV Booster 0.5 mL IM Anterolateral mid-thigh (right)
  • fIPV-3 (as updated) 0.1 mL Intradermal (ID) Right Upper Arm
  • Vitamin A 1st Dose 1 mL (1 lakh IU) Oral Mouth
  • 16–24 Months MR 2nd Dose 0.5 mL Subcutaneous (SC) Right Upper Arm
  • DPT Booster-1 0.5 mL IM Anterolateral mid-thigh (left)
  • OPV Booster 2 drops Oral Mouth
  • JE 2nd Dose 0.5 mL Subcutaneous (SC) Left Upper Arm
  • Vitamin A 2nd Dose 2 mL (2 lakh IU) Oral Mouth
  • 5–6 Years DPT Booster-2 0.5 mL IM Upper Arm (Deltoid)
  • 10 & 16 Years Td (Tetanus & adult Diphtheria) 0.5 mL IM Upper Arm (Deltoid)
  • Pregnant Women Td-1 & Td-2 (4 wks apart) 0.5 mL IM Upper Arm (Deltoid)
  • Specific Vaccine Characteristics & Clinical Nuances
  • 1. BCG (Bacillus Calmette-Guérin)

Strain : Live attenuated Mycobacterium bovis (Danish 1331 / Gothenburg strain).

Reconstitution : Must be reconstituted ONLY with Normal Saline (0.9% NaCl) . Never use Distilled Water, which causes local spinal tissue swelling, irritation, or micro-hemolysis.

Dose : 0.05 mL if administered at birth up to 1 month of age; 0.1 mL if administered after 1 month up to 1 year.

Normal Reaction : Papule forms at 2–3 weeks → Induration/Nodule → Vesicle/Pustule at 5–6 weeks → Shallow Ulceration → Permanent Punctate Depressed Scar healed by 6–12 weeks.

Koch's Phenomenon : Accelerated BCG reaction occurring within 24–48 hours in a child already infected with Tuberculosis or previously vaccinated.

2. Polio Vaccines (bOPV & fIPV)

bOPV : Bivalent Oral Polio Vaccine containing live attenuated Sabin strains of Types 1 and 3 (Type 2 was withdrawn globally during 'The Switch' in April 2016 to prevent circulating Vaccine-Derived Poliovirus - cVDPV2).

fIPV : Fractional Inactivated Polio Vaccine (Salk strain). Administered intradermally at 0.1 mL (1/5th of full 0.5 mL dose) at 6 and 14 weeks. Intradermal delivery targets dermal dendritic cells, inducing systemic and mucosal immunity equal to full IM dose.

3. Measles-Rubella (MR) Vaccine

Live attenuated lyophilized vaccine reconstituted with Sterile Water for Injection .

Administered Subcutaneously (SC) in right upper arm.

4-Hour Rule : Reconstituted MR, BCG, and JE vaccines MUST be kept cold (+2 to +8°C) and DISCARDED strictly after 4 hours (or at the end of the session, whichever is earlier) due to risk of Toxic Shock Syndrome caused by Staphylococcus aureus contamination.

4. Pentavalent Vaccine

Combines DPT + Hepatitis B + Hib in a liquid single/multi-dose vial.

Freeze-Sensitive : Must NEVER be frozen. Freezing denatures the aluminum adjuvant, causing irreversible loss of potency and severe local sterile abscesses.

Cold Chain System, Open Vial Policy & AEFI Management

The cold chain is a continuous system of transporting and storing vaccines at recommended temperatures from the point of manufacture to the point of administration.

Cold Chain Equipment & Storage Architecture

Cold Chain Level Primary Equipment Temperature Range

State / Regional Depot Walk-in Coolers (WIC) & Walk-in Freezers (WIF) +2°C to +8°C (WIC) / -15°C to -25°C (WIF)

  • District / PHC Level Ice-Lined Refrigerator (ILR) +2°C to +8°C (Primary storage for all UIP vaccines)
  • Deep Freezer -15°C to -25°C (For freezing ice packs and OPV storage)

Sub-centre / Outreach Vaccine Carrier / Day Carrier with 4 Conditioned Ice Packs +2°C to +8°C (Holds vaccines during field sessions)

ILR Loading Principles :

Top Section : Holds heat-sensitive vaccines ( OPV, MR, BCG ).

Bottom Section : Holds freeze-sensitive vaccines ( HepB, Pentavalent, DPT, TT/Td, PCV ).

Vaccines must be placed in baskets, keeping a 2 cm air gap from the walls.

  • Vaccine Vial Monitor (VVM) & Shake Test
  • Vaccine Vial Monitor (VVM) Stages

VVM is a thermo-chromic label printed on the vial that changes color as the vaccine is exposed to cumulative heat over time.

Stage 1 (Usable) : Inner square is much lighter than outer circle.

Stage 2 (Usable) : Inner square is still lighter than outer circle (Use this vial FIRST).

Stage 3 (DO NOT USE) : Inner square matches the color of outer circle (DISCARD!).

Stage 4 (DO NOT USE) : Inner square is darker than outer circle (DISCARD!). [Stage 1: Light Square] ==> [Stage 2: Pale Square] ==> [Stage 3: MATCHED] ==> [Stage 4: Dark Square]

  • (USABLE) (USABLE FIRST) (DISCARD VIAL) (DISCARD VIAL)
  • The Shake Test

Used to determine if a freeze-sensitive vaccine (Pentavalent, HepB, DPT, Td, PCV) has suffered damage due to accidental freezing:

Take a suspected frozen vial and a control vial (never frozen) from the same manufacturer.

Freeze the control vial completely, then thaw it.

Shake both vials vigorously for 10–15 seconds and place them side-by-side on a flat surface.

Observation : If the suspected vial clears rapidly and a thick flocculant sediment settles to the bottom faster than the control vial, the test is POSITIVE → Vaccine frozen and damaged → DISCARD VIAL .

Open Vial Policy (OVP)

Under India's National Open Vial Policy, opened multi-dose vials of specific vaccines can be kept and used for up to 28 days , provided:

Expiry date has not passed.

Vaccines are stored at +2°C to +8°C.

VVM inner square is lighter than outer circle.

Vaccine septum has not been submerged in water.

Aseptic technique was maintained.

Vaccines COVERED under Open Vial Policy (28 Days)

bOPV, fIPV, Pentavalent, DPT, Td, Hepatitis B, PCV .

Vaccines EXCLUDED from Open Vial Policy (Discard within 4 Hours!)

Reconstituted Live Vaccines : BCG, MR (Measles-Rubella), JE, and Rotavirus (liquid/lyophilized) MUST be discarded at the end of 4 hours or session end.

Adverse Events Following Immunization (AEFI): Anaphylaxis Protocol

An adverse event following immunization is any untoward medical occurrence following immunization.

Classification of AEFI

Vaccine product-related reaction : Inherent pharmacological property (e.g., mild fever after DPT).

Vaccine quality defect-related reaction : Manufacturing defect.

Immunization error-related reaction (Programmatic Error) : Inappropriate reconstitution (e.g., using non-sterile diluent causing abscess/TSS).

Immunization anxiety-related reaction : Vasovagal syncope in older children.

Coincidental reaction : Illness occurring post-vaccination by chance.

AEFI Anaphylaxis Emergency Protocol

Clinical Features : Rapid onset (within minutes to 30 mins) of bronchospasm, stridor, urticaria, facial angioedema, hypotension, and collapse.

FIRST-LINE DRUG OF CHOICE : Adrenaline (Epinephrine) 1:1000 dilution (1 mg/mL) .

Route & Site : Intramuscular (IM) into the Anterolateral Mid-Thigh .

Dose : 0.01 mg/kg (equivalent to 0.01 mL/kg of 1:1000 solution).

  • Infant < 2 years: 0.05 to 0.1 mL
  • Child 2–5 years: 0.15 to 0.2 mL
  • Child 6–12 years: 0.3 mL

Repeat every 5–15 minutes if clinical response is inadequate. Keep patient supine with legs elevated.

Loading diagram... Universal Immunization Cold Chain, VVM Stage & Open Vial Policy Decision Matrix